Abstract 114P
Background
Therapeutic management of locally advanced gastric cancer (LAGC) combines surgery with neo-adjuvant (NACT) and adjuvant chemotherapy (ACT). miRNAs have emerged as promising candidates for treatment efficacy prediction, hence, the present study aims at defining therapy response-specific profiles of circulating miRNAin LAGC.
Methods
A prospective cohort of 26 LAGC patients scheduled for NACT, surgery and ACT treatment was considered. Peripheral blood samples were collected prior to (preNACT) and after NACT (postNACT) as well as after tumor surgical excision and by completion of ACT (postACT). Patients were grouped according to Becker’s tumor regression grade criteria into responders (R;TRG1-2) and non-responders (NR;TRG3). Serum RNA was isolated with magnetic bead technology and relative expression levels of miR21a, mir19a, mir20a, miR30a & miR15a were determined by qRT-PCR.
Results
PreNACT profiles revealed expression differences between R and NR patient groups, with Responders characterized by elevated miR21a and, particularly, miR30a and miR15a expression levels as compared to NR. In response to NACT, miR15a & miR30a downregulation was the most distinguished difference defining Responders. R profile also showed a distinct upregulation of mir21a and elevation of the initially low levels of mir20a & mir19a. In contrast, NR showed NACT-dependent upregulation of all targets except miR19a. Interestingly, it was surgical depletion of primary tumor that first led to a marked activation of studied miRNAs in both R and NR patients, an upregulation found further augmented after ACT treatment. Nevertheless, postACT miR15a and miR30a levels in R remained substantially lower than in NR, evidence adding to their potential as chemosensitivity indicators.
Conclusions
This study aimed at monitoring the consequential to oncological and surgical therapy response-dependent expression patterns of a panel of circulating miR and, despite the small case series, revealed the potential of, particularly, miR15a and miR30a as chemosensitivity predictors in LAGC. The evidence merits further investigation in larger patient cohorts to validate their clinical utility as biomarkes for stratifying GC patients for precision therapy.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
National and Kapodistrian University of Athens, Greece.
Funding
ERAPerMed 2019-GRAMMY ERA Per Med - Joint Transnational Call for Proposals (2019) for “Personalised Medicine: Multidisciplinary Research Towards Implementation”.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis
Presenter: Eric Nakamura
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Identification of potential predictive biomarkers for ovarian cancer chemotherapy response
Presenter: Alsina Nurgalieva
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Rare RAS mutations are associated with recurrence patterns and recurrence-free survival in colon cancer: First results from Morocco
Presenter: Fatima Agy
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Development of a predictive model for response to neoadjuvant chemoradiation therapy of rectal cancer using the immunologic profile
Presenter: Eun Shin
Session: Cocktail & Poster Display session
Resources:
Abstract
152P - Biomarkers of neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
Presenter: Cibele Masotti
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - BRAF variants and therapy outcomes in melanoma
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - The impact of proton pump inhibitors in the prognosis of patients with non-metastatic nasopharyngeal carcinoma
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
155P - Use of machine learning for the identification of molecular biomarkers to predict response to neoadjuvant chemotherapy in locally advanced breast cancer patients
Presenter: María Del Río Pisula
Session: Cocktail & Poster Display session
Resources:
Abstract
156P - Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
Presenter: Michal Eid
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract